18 September 2018 - Ilumetri demonstrates lasting efficacy and safety through 3 years according to the positive results of a pooled analysis 2 of two phase-3 clinical trials.

Sun Pharmaceutical Industries today announced that Almirall has received the European Commission approval for Ilumetri (tildrakizumab) for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy. 

As indicated by Almirall, roll out of Ilumetri in Europe will start in the next few weeks. In July 2016, Sun Pharma out-licensed tildrakizumab to Almirall, for the development and commercialisation of the product for psoriasis in Europe.

Read Sun Pharma press release